GNMX Aevi Genomic Medicine, Inc.

4.91
-0.16  -3.16%
Previous Close 5.07
Open 5.14
Price To book 4.39
Market Cap 182.15M
Shares 37,097,000
Volume 221,045
Short Ratio 5.93
Av. Daily Volume 175,163

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 commencement of enrollment announced January 31, 2017.
AEVI-001 (NFC-1)
22q11.2 Deletion Syndrome
Phase 2/3 completion of enrollment announced January 4, 2017. Data are due 1Q 2017.
NFC-1 - SAGA
mGluR mutation positive ADHD